Highlights

  • Adherium (ASX:ADR) develops digital respiratory health technology through the Hailie platform.
  • The platform combines inhaler sensors with software to monitor medication use.
  • Remote patient monitoring Revenue has become a key part of the company’s strategy.
  • Patient activation, reimbursement and funding remain important areas to monitor.

Adherium Limited (ASX:ADR) is a digital respiratory health company focused on improving medication management for people with asthma and chronic obstructive pulmonary disease (COPD). Its Hailie platform combines connected inhaler sensors with digital software tools to support respiratory care monitoring. This article examines the company’s transition towards a recurring remote patient monitoring model.

The Hailie Digital Respiratory Platform

Adherium’s Hailie platform uses sensors attached to inhalers to capture medication usage information and provide data through connected software systems. The technology is designed to help healthcare providers understand patient adherence and support respiratory disease management.

The company’s approach is based on moving beyond traditional device sales towards ongoing digital health services supported by remote monitoring.

Remote Patient Monitoring Expansion

Adherium has focused on expanding its remote patient monitoring revenue model, particularly within the United States healthcare system. The company reported increasing remote patient monitoring revenue and growth in activated patient numbers during 2026.

The Business model depends on converting eligible patients into active users of the platform and maintaining ongoing reimbursement support from healthcare providers and insurers.

Clinical Applications and Market Opportunity

Respiratory diseases such as asthma and COPD require long-term management, making medication adherence an important part of patient care. Adherium’s platform is designed to provide healthcare professionals with additional information about patient medication usage.

The company has also highlighted evidence from healthcare programmes using its technology. Broader adoption will depend on continued clinical validation, healthcare provider engagement and reimbursement arrangements.

Funding and Commercial Considerations

Adherium remains a developing healthcare technology company requiring Investment to expand commercial operations. The company’s ability to grow depends on patient activation rates, payer relationships and managing operating expenses.

The gap between potential patient pipelines and active revenue-generating users remains an important consideration as the company scales its platform.

Key Insights

Adherium is building a digital respiratory healthcare model centred on connected inhaler technology and recurring monitoring services. The company’s future progress depends on converting platform adoption into sustainable revenue while managing the operational requirements of expansion.